Hormone Therapy That Lowers Breast Cancer Risk By 23%

A hormone drug once feared as a cancer trigger just got a 23% reduction in breast cancer diagnoses tied to its name in long-term federal research.

Quick Take

Long-term follow-up of the Women’s Health Initiative found estrogen-only hormone therapy linked to a 23% lower rate of breast cancer diagnoses.
The same follow-up found lower breast cancer deaths among women who took estrogen alone versus a placebo.
The benefit applies specifically to estrogen-only pills, taken by women who have had a hysterectomy, not combined estrogen-progestin therapy.
Doctors say the two therapy types work differently in the body, which may explain why the results diverge so sharply.

What The Long-Term Trial Actually Found

The Women’s Health Initiative followed thousands of postmenopausal women for two decades. Women taking conjugated equine estrogen alone, without progestin, showed a statistically significant drop in invasive breast cancer compared to women on a placebo. The National Institutes of Health confirmed the estrogen-only group did not face a higher cancer risk in updated analysis of the trial data.

Researchers tracking the group for roughly sixteen years reported women on estrogen-only therapy were 23% less likely to be diagnosed with breast cancer. Twenty-year follow-up data went further, tying the therapy to a lower breast cancer death rate as well, with a hazard ratio suggesting death risk dropped by around 40% in that group.

Why This Only Applies To One Type Of Hormone Pill

Here’s the catch that makes this story complicated instead of simple. Estrogen-only therapy is prescribed almost exclusively to women who no longer have a uterus, typically after a hysterectomy. Women who still have a uterus generally need progestin added to protect against uterine cancer. That combined regimen is a different drug with a different track record entirely.

A review of randomized trial data concluded the overall body of evidence “supports a conclusion that estrogen-alone use significantly reduces breast cancer incidence,” while separate trial arms testing combined estrogen-progestin therapy showed increased risk instead. Breastcancer.org’s own guidance draws that same hard line, stating combination therapy taken five years or longer raises risk while estrogen-only therapy does not.

The Fear That Won’t Fade From 2002

Any conversation about hormone therapy still carries the ghost of 2002, when the original Women’s Health Initiative results made headlines and hormone prescriptions collapsed nationwide. The American College of Obstetricians and Gynecologists issued a statement at the time warning of a “true increased risk” for breast cancer among women taking combined estrogen and progestin, and said all hormone therapy patients deserved to know it.

That warning was accurate for the combined regimen. But it got applied broadly in public memory, lumping estrogen-only therapy into the same bucket of suspicion for years afterward. A woman deciding on hormone therapy today is often working from a headline that never distinguished which drug was actually dangerous.

What Women And Doctors Should Take From This

The randomized trial data on estrogen-only therapy after hysterectomy is the strongest evidence available, and it leans favorable. But the benefit is not automatic, not universal, and appears tied to a specific drug, dose, and patient group studied decades ago. Women considering hormone therapy deserve a conversation with their doctor grounded in their own history, not a headline number pulled from one trial average.

Common sense says this story deserves nuance instead of panic or celebration. Combined therapy carries real, documented risk. Estrogen-only therapy, in the population actually studied, appears to lower risk rather than raise it. Conflating the two, in either direction, does a disservice to the millions of women trying to make an informed decision about their own health.